We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Battery-Free Device Implanted Through Minimally-Invasive Procedure Treats Bladder Leaks

By HospiMedica International staff writers
Posted on 24 Sep 2024
Print article
Image: The small, battery-free implant is placed near the ankle in a single-step procedure (Photo courtesy of BlueWind Medical)
Image: The small, battery-free implant is placed near the ankle in a single-step procedure (Photo courtesy of BlueWind Medical)

Urinary urgency incontinence (UUI), a chronic and often debilitating condition, affects millions and can greatly disrupt daily life. Current treatments aimed at improving bladder control, such as medications and surgical interventions, often come with drawbacks, including side effects or limitations Now, an innovative Implantable Tibial NeuroModulation (iTNM) device offers an exciting new treatment option that could provide relief for patients with UUI.

The Revi Implant, developed by BlueWind Medical (Park City, UT, USA), is a small, battery-free device implanted near the ankle during a minimally invasive outpatient procedure under local anesthesia. Once implanted, the device stimulates the posterior tibial nerve to help alleviate UUI symptoms. Activation of the Revi Implant is simple: a lightweight wireless wearable is placed around the ankle once or twice a day, allowing patients to receive stimulation at their convenience. The battery-free design allows the Revi Implant to be miniaturized, measuring just 3 cm in length and 3 mm in diameter, which eliminates the need for future surgeries to address issues such as battery depletion, lead fractures, or migration.

Last year, the U.S. Food and Drug Administration (FDA) granted De Novo marketing authorization for the Revi System for men and women suffering from UUI. This approval was based on results from the OASIS pivotal trial, where Revi showed statistically significant symptom reduction and a favorable safety profile compared to baseline. Revi stands out as the only neuromodulation therapy that gives physicians the flexibility to decide if patients should try more conservative treatments before using the Revi System, rather than advising them to undergo "step-therapy."

Related Links:
BlueWind Medical

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
ECG Air Suction Unit
ECG Air / BT
New
Washer Disinfector
Tiva 2

Print article

Channels

Surgical Techniques

view channel
Image: Molecular imaging of the adrenal glands in three patients (Photo courtesy of QMUL)

Endoscopic Ultrasound-Guided Procedure Could Transform Blood Pressure Management

Primary aldosteronism (PA) is a hormonal disorder that causes high blood pressure in approximately one in 20 patients with hypertension but often goes undiagnosed and untreated. In this condition, benign... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.